QALQONSIMON BEZ SARATONINING KLINIK KECHUVI XUSUSIYATLARIGA BOG‘LIQ HOLDA INTERLEYKINLAR DINAMIKASINI BAHOLASH
DOI:
https://doi.org/10.5281/zenodo.22766746Keywords:
qalqonsimon bez saratoni, IL-6, TNF-α, IL-10, sitokinlar, immunologik biomarkerlar, o‘sma progressiyasi, kasallik bosqichi, metastazlanishAbstract
Tadqiqot qalqonsimon bez saratoni (QBS) klinik kechishining turli bosqichlarida IL-6, TNF-α va IL-10 sitokinlari dinamikasini baholashga bag‘ishlangan. Tadqiqotning maqsadi kasallikning ilk va kechki bosqichlarida mazkur sitokinlar darajasidagi o‘zgarishlarni aniqlash va ularning o‘sma jarayonining tarqalganligi bilan bog‘liqligini baholashdan iborat. QBS bilan kasallangan bemorlarda IL-6, TNF-α va IL-10 konsentratsiyalarining sog‘lom shaxslarga nisbatan statistik jihatdan ishonchli yuqori ekanligi aniqlandi (p<0,05). Kasallik bosqichi oshishi bilan barcha o‘rganilgan sitokinlarning izchil ko‘payishi, ayniqsa III–IV bosqichlarda yaqqol namoyon bo‘lishi kuzatildi. IL-6 darajasi I–II bosqichlardagi 21,33±1,52 pg/ml dan III–IV bosqichlarda 52,59±5,11 pg/ml gacha, TNF-α esa 9,64±1,55 pg/ml dan 25,45±3,22 pg/ml gacha oshdi. IL-10 konsentratsiyasi mos ravishda 19,05±1,66 pg/ml dan 28,55±3,42 pg/ml gacha ko‘tarilib, 49,9% o‘sishni tashkil etdi. Mualliflik yondashuvining o‘ziga xosligi ushbu sitokinlarni alohida laborator ko‘rsatkichlar sifatida emas, balki QBSning klinik bosqichi va o‘sma jarayoni faolligini aks ettiruvchi kompleks immunologik mezonlar sifatida baholashdan iborat. Tadqiqotning ilmiy yangiligi IL-6, TNF-α va IL-10 dinamikasidan QBS agressivligi, tarqalganligi va metastazlanish xavfini baholashda qo‘shimcha prognostik biomarkerlar sifatida foydalanish istiqbolini asoslash bilan belgilanadi.References
1. Baker, K. J., Houston, A., & Brint, E. (2019). IL-1 family members in cancer; two sides to every story. Front Immunol. 2019; 10:1197. doi: 10.3389/fimmu.2019.01197. https://doi.org/10.3389/fimmu.2019.01197
2. Bastman, J. J., Serracino, H. S., Zhu, Y., Koenig, M. R., Mateescu, V., Sams, S. B., Davies, K. D., Raeburn, C. D., McIntyre, R. C., Haugen, B. R., et al. (2016). Tumor infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab, 101, 2863–2873.
3. Beatty, G. L., & Gladney, W. L. (2015). Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res, 21, 687–692.
4. Beksac, K., Sonmez, C., Cetin, B., Kismali, G., Sel, T., Tuncer, Y., et al. (2016). Evaluation of proinflammatory cytokine and neopterin levels in women with papillary thyroid carcinoma. Int J Biol Markers. 2016; 31:e446–e450. doi: 10.5301/jbm.5000214. 10.5301/jbm.5000214. https://doi.org/10.5301/jbm.5000214
5. Bonavita, E., Galdiero, M. R., Jaillon, S., & Mantovani, A. (2015). Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. Adv Cancer Res, 128, 141–171.
6. Carvalho, D. F. G., Zanetti, B. R., Miranda, L., Hassumi-Fukasawa, M. K., Miranda-Camargo, F., Crispim, J. C. O., et al. (2017). High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer. Oncol Lett, 13, 1925–1931.
7. Chen, L., & Han, X. (2015). Anti–PD-1/PD-L1 therapy of human cancer: Past, present, and future. J Clin Investig, 125, 3384–3391.
8. Chong, S. T., Tan, K. M., Kok, C. Y. L., Guan, S. P., Lai, Sh., Lim, C., et al. (2019). IL13RA2 is differentially regulated in papillary thyroid carcinoma versus follicular thyroid carcinoma. J Clin Endocrinol Metab, 104, 5573–5584.
9. Cunha, L. L., Morari, E. C., Nonogaki, S., Marcello, M. A., Soares, F. A., Vassallo, J., et al. (2017). Interleukin 10 expression is related to aggressiveness and poor prognosis of patients with thyroid cancer. Cancer Immunol Immunother, 66, 141–148. https://doi.org/10.1007/s00262-016-1924-4
10. Cunha, L. L., Marcello, M. A., Nonogaki, S., Morari, E. C., Soares, F. A., Vassallo, J., & Ward, L. S. (2015). CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer. Clin Endocrinol, 83, 246–253.
11. Galdiero, M. R., Varricchi, G., Loffredo, S., Mantovani, A., & Marone, G. (2018). Roles of neutrophils in cancer growth and progression. J Leukoc Biol, 103, 457–464.
12. Galdiero, M. R., Varricchi, G., Seaf, M., Marone, G., Levi-Schaffer, F., & Marone, G. (2017). Bidirectional mast cell-eosinophil interactions in inflammatory disorders and cancer. Front Med. 2017; 4:103.
13. Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016). Targeting natural killer cells in cancer immunotherapy. Nat Immunol, 17, 1025–1036.
14. Ibana, J. A., Cutay, S. J., Romero, M., & Schust, D. J. (2016). Parallel expression of enzyme inhibitors of CD8T cell activity in tumor microenvironments and secretory endometrium. Reprod Sci, 23, 289–301.
15. Pilli, T., Toti, P., Occhini, R., Castagna, M. G., Cantara, S., Caselli, M., Cardinale, S., Barbagli, L., & Pacini, F. (2018). Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: The potential key role of Foxp3+ T lymphocytes. J Endocrinol Investig, 41, 703–709.
16. Varricchi, G., Galdiero, M. R., Loffredo, S., Marone, G., Iannone, R., Marone, G., & Granata, F. (2017). Are mast cells MASTers in cancer? Front Immunol. 2017; 8:424.
17. Wikberg, M. L., Ling, A., Li, X., Oberg, A., Edin, S., & Palmqvist, R. (2017). Neutrophil infiltration is a favorable prognostic factor in early stages of colon cancer. Hum Pathol, 68, 193–202.
18. Zhao, S. G., Lehrer, J., Chang, S. L., Das, R., Erho, N., Liu, Y., Sjöström, M., Den, R. B., Freedland, S. J., Klein, E. A., et al. (2019). The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst, 111(9), 301–310.

